Global Blood Therapeutics, Inc.
Histone methyltransferase inhibitors

Last updated:

Abstract:

The present disclosure provides certain compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies such as beta-thalassemia and sickle cell disease. Also provided are pharmaceutical compositions containing such compounds as well as processes and intermediates for preparing such compounds.

Status:
Grant
Type:

Utility

Filling date:

15 Feb 2017

Issue date:

22 Feb 2022